NDATOPICALCREAM
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ULTRAVATE (halobetasol propionate) by PharmaIN is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Approved for psoriasis. First approved in 1990.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRAVATE (halobetasol propionate) is a potent topical corticosteroid cream approved in 1990 for the treatment of plaque psoriasis. It works by modulating cellular signaling, immune function, inflammation, and protein regulation, though its precise mechanism in psoriasis remains incompletely understood. The drug is administered topically as a cream formulation.
$0.173MPart D
LOE ApproachingDeclining
ULTRAVATE is in late-stage lifecycle with modest spending and declining market share, indicating potential team consolidation and defensive commercial strategy.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Indications (1)
Clinical Trials (2)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Started Apr 2016
154 enrolled
Psoriasis
Career Relevance
Worked on ULTRAVATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.